Natrunix
Phase 2Small molecule
Natrunix is one of 63 small molecule programs targeting Arthritis. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
62
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
791 competitors in Rheumatoid Arthritis
#DrugCompanyPhaseTrials
1Actemra
RochePreclinical
Enbrel
IImmunex
Preclinical
Remicade
OOrganon and Co
Preclinical
Arcoxia
NovartisPreclinical
Actos
TakedaPreclinical
Celexa
AbbViePreclinical
Rituxan
PfizerPreclinical
Natrunix
XXBiotech, Inc.
Phase 2
Velcade
SShilpa Grover, MD, MPH
Preclinical
Vancocin
HHikma Pharmaceuticals LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Natrunix. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- XXBiotech, Inc.